Literature DB >> 2910246

Results of surgical excision of one to 13 hepatic metastases in 98 consecutive patients.

J P Minton1, W B Hamilton, A Sardi, C Nieroda, B Sickle-Santanello, P J O'Dwyer.   

Abstract

Metastatic carcinoma to the liver is generally considered to be associated with a poor prognosis, with five-year survival of only 20% to 30% after resection of solitary lesions. Ninety-eight consecutive patients underwent the surgical removal of one to 13 metastatic lesions from the liver. A rising carcinoembryonic antigen level was considered an indication for reexploration. All gross tumor was removed in every patient; 66 had more than one metastasis. Survival was unexpectedly high: 91 of 98 were alive at 12 months, 50 (70%) of 71 at 13 to 24 months, 23 (66%) of 36 at 25 to 36 months, 14 (74%) of 19 at 37 to 48 months, six (60%) of ten at 49 to 60 months, four (80%) of five at 61 to 72 months, and two (50%) of four 73 to 84 months after resection of multiple liver metastases. The procedure appears to be a safe and, in some patients, beneficial surgical technique for the removal of multiple hepatic metastases.

Entities:  

Mesh:

Year:  1989        PMID: 2910246     DOI: 10.1001/archsurg.1989.01410010052012

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  4 in total

Review 1.  Resection of colorectal liver metastases revisited.

Authors:  J Scheele; C Rudroff; A Altendorf-Hofmann
Journal:  J Gastrointest Surg       Date:  1997 Sep-Oct       Impact factor: 3.452

Review 2.  General surgery.

Authors:  I Taylor
Journal:  Postgrad Med J       Date:  1990-05       Impact factor: 2.401

3.  Formal hepatic resection of colorectal liver metastases. Ploidy and prognosis.

Authors:  D S Lind; G A Parker; J S Horsley; M J Kornstein; J P Neifeld; H D Bear; W Lawrence
Journal:  Ann Surg       Date:  1992-06       Impact factor: 12.969

4.  Prediction of surgical resectability in patients with hepatic colorectal metastases.

Authors:  S B Vogel; W E Drane; P R Ros; S R Kerns; K I Bland
Journal:  Ann Surg       Date:  1994-05       Impact factor: 12.969

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.